Hemophagocytic Lymphohistiocytosis Completed Phase 2 Trials for Cyclophosphamide (DB00531)

Back to Hemophagocytic Lymphohistiocytosis

Also known as: Hemophagocytic Lymphohistiocytosis (HLH) / Haemophagocytic Lymphohistiocytosis / Hemophagocytic Lymphohistiocytoses / Hemophagocytic Lymphohisticytosis / Hemophagocytic lymphohistiocytosis (disorder) / Lymphohistiocytosis, Hemophagocytic / Primary hemophagocytic lymphohistiocytosis / Primary haemophagocytic lymphohistiocytosis / Familial hemophagocytic lymphohistiocytosis (disorder) / Familial Hemophagocytic Lymphocytosis / Familial haemophagocytic lymphohistiocytosis / Familial hemophagocytic lymphohistiocytosis

Indication	Status	Phase
DBCOND0029166 (Hemophagocytic Lymphohistiocytosis)	Completed	2

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT00368355	T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts	Treatment	Alemtuzumab (DB00087) Cyclophosphamide (DB00531) Cytarabine (DB00987)